|
Cryoport Inc 's Leverage Ratio
CYRX's quarterly Leverage Ratio and Total Liabilities, Equity growth
Due to net new borrowings of 1.21%, Leverage Ratio fell to 0.96, above the Cryoport Inc 's average Leverage Ratio.
Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 101 other companies have achieved lower Leverage Ratio than Cryoport Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 1001, from total ranking in the third quarter 2023 at 1681 .
Explain Leverage Ratio?
Who are CYRX Customers?
What are CYRX´s Total Liabilities?
Select the Comparisons :
|
|
Select the Ratio:
|
|
CYRX Leverage Ratio |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity Change |
-12.02 % |
-3.27 % |
-4.25 % |
-8.03 % |
-13.4 % |
Y / Y Total Liabilities Change |
-2.07 % |
-2.38 % |
2.52 % |
4.21 % |
2.49 % |
Leverage Ratio MRQ |
0.96 |
0.86 |
0.89 |
0.87 |
0.86 |
CYRX's Total
Ranking |
# 1001 |
# 1681 |
# 1830 |
# 1867 |
# 2125 |
Seq. Equity Change |
-9.02 % |
-1.24 % |
-2.9 % |
0.84 % |
0.02 % |
Seq. Total Liabilities Change |
1.21 % |
-4.78 % |
-0.25 % |
1.87 % |
0.89 % |
Leverage Ratio forth quarter 2023 Company Ranking |
Within: |
No. |
Major Pharmaceutical Preparations Industry |
# 102 |
Healthcare Sector |
# 236 |
Overall Market |
# 1001 |
Leverage Ratio Statistics |
High |
Average |
Low |
5.8 |
0.71 |
0.07 |
(Dec 31 2011) |
|
(Dec 31 2019) |
Cumulative Cryoport Inc 's Leverage Ratio
CYRX's Leverage Ratio for the trailling 12 Months
CYRX Leverage Ratio |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity TTM Growth |
-12.02 % |
-3.27 % |
-4.25 % |
-8.03 % |
-13.4 % |
Y / Y Total Liabilities TTM Growth |
-2.07 % |
-2.38 % |
2.52 % |
4.21 % |
2.49 % |
Leverage Ratio TTM |
0.89 |
0.87 |
0.87 |
0.85 |
0.83 |
Total
Ranking TTM |
# 849
| # 8
| # 1553
| # 6
| # 699
|
Seq. Equity TTM Growth |
-9.02 % |
-1.24 % |
-2.9 % |
0.84 % |
0.02 % |
Seq. Total Liabilities TTM Growth |
1.21 % |
-4.78 % |
-0.25 % |
1.87 % |
0.89 % |
On the trailing twelve months basis Due to the net new borrowings of 1.21% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLeverage Ratio improved to 0.89, above the Cryoport Inc 's average Leverage Ratio. Leverage Ratio is the average cumulative value over the last four quarters.
Among companies in the Major Pharmaceutical Preparations industry 86, during the past 12 months, other companies have achieved lower Leverage Ratio than Cryoport Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 8 to 849.
Explain Leverage Ratio?
Who are CYRX Customers?
What are CYRX´s Total Liabilities?
TTM Leverage Ratio Company Ranking |
Within: |
No. |
Within the Major Pharmaceutical Preparations Industry |
# 87 |
Healthcare Sector |
# 214 |
Within the Market |
# 849 |
trailing twelve months Leverage Ratio Statistics |
High |
Average |
Low |
1.41 |
0.48 |
0.12 | (Sep. 30, 2015) |
|
(Sep 30 2018) |
Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry | Leverage Ratio | Dec 31 2023 MRQ Total Liabilities | Dec 31 2023 MRQ Equity | G1 Therapeutics Inc | 2.43 | $ 86.154 Millions | $ 35.386 Millions | Proqr Therapeutics N v | 2.33 | $ 108.072 Millions | $ 46.357 Millions | Phibro Animal Health Corporation | 2.31 | $ 626.625 Millions | $ 270.803 Millions | Bristol myers Squibb Company | 2.23 | $ 65,729.000 Millions | $ 29,485.000 Millions | Alimera Sciences Inc | 2.00 | $ 92.218 Millions | $ 46.170 Millions | Biovie Inc | 1.87 | $ 13.981 Millions | $ 7.491 Millions | Zoetis Inc | 1.86 | $ 9,289.000 Millions | $ 4,991.000 Millions | Emergent Biosolutions Inc | 1.81 | $ 1,173.900 Millions | $ 649.300 Millions | Jazz Pharmaceuticals Plc | 1.78 | $ 6,644.680 Millions | $ 3,736.997 Millions | Catalent Inc | 1.71 | $ 6,301.000 Millions | $ 3,687.000 Millions | Xoma Corporation | 1.64 | $ 145.580 Millions | $ 88.721 Millions | Summit Therapeutics Inc | 1.61 | $ 125.257 Millions | $ 77.692 Millions | Cumberland Pharmaceuticals Inc | 1.59 | $ 46.528 Millions | $ 29.260 Millions | Merck and Co Inc | 1.58 | $ 59,431.000 Millions | $ 37,635.000 Millions | Pfizer Inc | 1.54 | $ 137,487.000 Millions | $ 89,288.000 Millions | Ocular Therapeutix Inc | 1.54 | $ 139.916 Millions | $ 91.131 Millions | Liquidia Corporation | 1.50 | $ 71.039 Millions | $ 47.293 Millions | Viatris Inc | 1.33 | $ 27,218.100 Millions | $ 20,467.400 Millions | Lifevantage Corp | 1.30 | $ 35.375 Millions | $ 27.307 Millions | Verastem inc | 1.24 | $ 71.185 Millions | $ 57.374 Millions | 2seventy Bio Inc | 1.21 | $ 310.126 Millions | $ 255.300 Millions | Cara Therapeutics inc | 1.20 | $ 68.759 Millions | $ 57.085 Millions | Sonoma Pharmaceuticals Inc | 1.18 | $ 7.926 Millions | $ 6.692 Millions | Perrigo Company Plc | 1.18 | $ 5,615.400 Millions | $ 4,767.900 Millions | Elanco Animal Health Inc | 1.16 | $ 7,205.000 Millions | $ 6,223.000 Millions | Johnson and Johnson | 1.16 | $ 79,590.000 Millions | $ 68,774.000 Millions | Novartis Ag | 1.14 | $ 53,195.000 Millions | $ 46,750.000 Millions | Ani Pharmaceuticals Inc | 1.09 | $ 471.673 Millions | $ 432.749 Millions | Prestige Consumer Healthcare Inc | 1.09 | $ 1,739.176 Millions | $ 1,600.577 Millions | Assertio Holdings inc | 1.08 | $ 148.416 Millions | $ 138.003 Millions |
|